Ginkgo has decent data for existing cognitive decline (dementia adjunct) but the massive GEM study found it doesn't prevent dementia in healthy older adults. Bacopa has more consistent positive trials for memory in healthy adults but takes 8-12 weeks to work. If you want a preventive herbal, Bacopa has better data. If you're supporting existing decline, ginkgo has a role.
What each is
Ginkgo biloba extract (usually the EGb 761 standardized extract) has been sold in Europe as a medical treatment for cognitive decline for decades. The standardization is 24% flavone glycosides and 6% terpene lactones. Active compounds include ginkgolides and bilobalide, which have antiplatelet and vasodilatory effects.
Bacopa monnieri (Brahmi) is an Ayurvedic herb standardized to bacoside content (usually 50-55% bacosides). Active mechanisms include serotonin and GABA modulation, BDNF increase, and antioxidant effects in the hippocampus specifically.
The trial evidence, compared
| Endpoint | Ginkgo Biloba (EGb 761) | Bacopa (Bacognize/Synapsa) |
|---|---|---|
| Prevention of dementia in healthy older adults | Negative (GEM Study 2008) | Not directly tested |
| Memory in healthy adults | Mixed | Positive (Stough 2001, 2008) |
| Adjunct in mild dementia | Modest positive (Le Bars 1997) | Not primary indication |
| Time to effect | Weeks | 8-12 weeks |
| Best-studied dose | 120-240 mg EGb 761 daily | 300 mg Synapsa or 320 mg Bacognize |
| Anxiety effect | Neutral | Positive |
| Bleeding risk | Yes (antiplatelet) | Minimal |
| GI side effects | Occasional | Common if taken without food |
The Ginkgo Evaluation of Memory (GEM) Study is the trial that reshaped the ginkgo conversation. DeKosky and colleagues randomized 3,069 older adults (75+) to 120 mg EGb 761 twice daily or placebo for a median of 6.1 years. The primary endpoint — incidence of all-cause dementia and Alzheimer's — showed no difference between groups.[1]
Before GEM, the strongest positive ginkgo trial was Le Bars 1997 — 309 patients with existing Alzheimer's or vascular dementia given 120 mg EGb 761 daily for 52 weeks. The ginkgo group showed modest improvements on ADAS-Cog vs placebo.[2] The pattern that emerged: ginkgo may help existing decline modestly, but doesn't prevent it.
Bacopa's Stough 2008 trial (90 days, 300 mg Bacopa in 62 healthy adults) showed significant improvements in delayed recall on the Rey Auditory Verbal Learning Test with no serious adverse events.[3] Roodenrys 2002 replicated the memory finding in a smaller trial.[4]
What GEM actually means
The GEM study's failure to show dementia prevention is often overinterpreted. What GEM showed:
- 240 mg EGb 761 daily does NOT prevent incident dementia in older adults over 6 years
- Ginkgo did NOT slow cognitive decline in the subgroup that developed cognitive impairment during the study
- No safety signals emerged that would preclude use
What GEM did NOT test:
- Ginkgo in already-cognitively-impaired patients (the Le Bars population)
- Ginkgo at higher doses (>240 mg/day)
- Ginkgo in combination with other interventions
- Ginkgo for short-term cognitive performance vs long-term prevention
The honest interpretation: for healthy older adults hoping to prevent decline, ginkgo doesn't earn its place based on current evidence. For existing decline as an adjunct, some role remains.
STRONG: Ginkgo does NOT prevent dementia in healthy older adults (GEM Study).MODERATE: Ginkgo as adjunct in mild-to-moderate existing dementia (Le Bars + smaller replications).MODERATE: Bacopa for memory consolidation in healthy adults (Stough trials).The bleeding risk with ginkgo
Ginkgo has documented antiplatelet effects. Case reports and controlled studies have identified increased bleeding risk with ginkgo alone at higher doses and clear interactions with:
- Warfarin
- Aspirin (including low-dose cardiac aspirin)
- Clopidogrel and other antiplatelets
- SSRIs (some evidence of increased bleeding risk)
- Fish oil at high doses (additive antiplatelet effect)
Bacopa doesn't have this concern. If you're on anticoagulants or antiplatelets, the choice between these two is largely made for you.
Where each fits
- Healthy adults wanting cognitive maintenance: Bacopa. Better prevention-relevant trial data.
- Existing mild-to-moderate cognitive decline: Ginkgo is a legitimate adjunct (not a primary treatment). Under physician supervision, especially if on other medications.
- Anticoagulated patients: Bacopa. Ginkgo's bleeding risk profile is a hard limit.
- Anxious with cognitive complaints: Bacopa. Anxiety-friendly, doesn't add bleeding risk.
- Peripheral circulation issues alongside cognitive complaints: Ginkgo has vasodilatory effects relevant to intermittent claudication that Bacopa doesn't.
Combining or sequencing
These two can be combined, but the interaction profile makes it worth checking. Ginkgo's antiplatelet effect is additive with anything else that thins blood — a full stack of fish oil + ginkgo + aspirin creates real bleeding risk.
Bacopa's slower onset (8-12 weeks for meaningful effect) means you shouldn't judge it after 2-3 weeks. Ginkgo's effects, if present, tend to appear within 4-6 weeks.
What to actually buy
Himalaya Bacopa (Bacognize)
Bacognize extract at clinical dose. Well-tolerated, extensive trial base, take with food.
Check Amazon price →Nature's Way Ginkgold (EGb 761 equivalent)
Standardized 24/6 ginkgo extract at 60 mg per tablet — take two twice daily for the Le Bars trial dose. This form is equivalent to what most positive trials used.
Check Amazon price →Life Extension Optimized Ashwagandha and Bacopa
Contains Synapsa Bacopa (55% bacosides) — the exact extract used in some positive human trials. Stacked with ashwagandha for a combined stress+memory formula.
Check Amazon price →Citations
- DeKosky ST, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-2262.
- Le Bars PL, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997;278(16):1327-1332.
- Stough C, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629-1634.
- Roodenrys S, et al. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279-281.
- Snitz BE, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 2009;302(24):2663-2670.
- Ihl R, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features. Int J Geriatr Psychiatry. 2011;26(11):1186-1194.